The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today launched a new program that offers financial support for individuals with inherited retinal diseases.
One of the largest interventional clinical trials for the treatment of STGD1, an inherited orphan retinal disease. Zimura is also being investigated in ongoing clinical trials for the treatment of dry and wet age-related macular degeneration (AMD), and idiopathic polypoidal choroidal vasculopathy (IPCV).
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. The Foundation is a beacon of hope for those affected by these blinding diseases. Join the fight and help us accelerate our mission.
Welcome to the new Foundation site — supported in partnership with Genentech, A Member of the Roche Group.
